Literature DB >> 21530750

Future therapeutic approaches for inflammatory bowel diseases.

Scott E Plevy1, Stephan R Targan.   

Abstract

In this review, we speculate about future therapeutic approaches for inflammatory bowel diseases (IBDs), focusing on the need for better preclinical and clinical models and approaches beyond small molecules and systemically administered biologics. We offer ideas to change clinical trial programs and to use immunologic and genetic biomarkers to personalize medicine. We attempt to reconcile past therapeutic successes and failures to improve future approaches. Some of our ideas might be provocative, but we hope that the examples we provide will stimulate discussion about what will advance the field of IBD therapy.
Copyright © 2011 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21530750      PMCID: PMC5076881          DOI: 10.1053/j.gastro.2011.02.014

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  60 in total

1.  Single nucleotide polymorphisms in TNFSF15 confer susceptibility to Crohn's disease.

Authors:  Keiko Yamazaki; Dermot McGovern; Jiannis Ragoussis; Marta Paolucci; Helen Butler; Derek Jewell; Lon Cardon; Masakazu Takazoe; Torao Tanaka; Toshiki Ichimori; Susumu Saito; Akihiro Sekine; Aritoshi Iida; Atsushi Takahashi; Tatsuhiko Tsunoda; Mark Lathrop; Yusuke Nakamura
Journal:  Hum Mol Genet       Date:  2005-10-12       Impact factor: 6.150

Review 2.  Tolerogenic dendritic cells for autoimmune disease and transplantation.

Authors:  A W Thomson; P D Robbins
Journal:  Ann Rheum Dis       Date:  2008-12       Impact factor: 19.103

Review 3.  Experimental basis of hematopoietic stem cell transplantation for treatment of autoimmune diseases.

Authors:  D W van Bekkum
Journal:  J Leukoc Biol       Date:  2002-10       Impact factor: 4.962

4.  Cutting edge: IFN-gamma is a negative regulator of IL-23 in murine macrophages and experimental colitis.

Authors:  Shehzad Z Sheikh; Katsuyoshi Matsuoka; Taku Kobayashi; Fengling Li; Tara Rubinas; Scott E Plevy
Journal:  J Immunol       Date:  2010-03-12       Impact factor: 5.422

Review 5.  Lessons from genetically engineered animal models. XII. IL-10-deficient (IL-10(-/-) mice and intestinal inflammation.

Authors:  D M Rennick; M M Fort
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2000-06       Impact factor: 4.052

6.  Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group.

Authors:  S Schreiber; R N Fedorak; O H Nielsen; G Wild; C N Williams; S Nikolaus; M Jacyna; B A Lashner; A Gangl; P Rutgeerts; K Isaacs; S J van Deventer; J C Koningsberger; M Cohard; A LeBeaut; S B Hanauer
Journal:  Gastroenterology       Date:  2000-12       Impact factor: 22.682

Review 7.  Insights into IBD Pathogenesis.

Authors:  David Q Shih; Stephan R Targan
Journal:  Curr Gastroenterol Rep       Date:  2009-12

8.  Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease.

Authors:  S H Murch; V A Lamkin; M O Savage; J A Walker-Smith; T T MacDonald
Journal:  Gut       Date:  1991-08       Impact factor: 23.059

9.  Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2).

Authors:  Kim A Papp; Richard G Langley; Mark Lebwohl; Gerald G Krueger; Philippe Szapary; Newman Yeilding; Cynthia Guzzo; Ming-Chun Hsu; Yuhua Wang; Shu Li; Lisa T Dooley; Kristian Reich
Journal:  Lancet       Date:  2008-05-17       Impact factor: 79.321

10.  Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4+ T cells.

Authors:  F Powrie; M W Leach; S Mauze; S Menon; L B Caddle; R L Coffman
Journal:  Immunity       Date:  1994-10       Impact factor: 31.745

View more
  22 in total

1.  An old herbal medicine with a potentially new therapeutic application in inflammatory bowel disease.

Authors:  Richard Li; Philip Alex; Mei Ye; Ting Zhang; Ling Liu; Xuhang Li
Journal:  Int J Clin Exp Med       Date:  2011-10-29

Review 2.  Potential prospects of nanomedicine for targeted therapeutics in inflammatory bowel diseases.

Authors:  Madharasi V A Pichai; Lynnette R Ferguson
Journal:  World J Gastroenterol       Date:  2012-06-21       Impact factor: 5.742

Review 3.  Optimal use and cost-effectiveness of biologic therapies in inflammatory bowel disease.

Authors:  Antonio Di Sabatino; Lucio Liberato; Monia Marchetti; Paolo Biancheri; Gino R Corazza
Journal:  Intern Emerg Med       Date:  2011-10       Impact factor: 3.397

Review 4.  Induced and natural regulatory T cells in the development of inflammatory bowel disease.

Authors:  Christopher G Mayne; Calvin B Williams
Journal:  Inflamm Bowel Dis       Date:  2013-07       Impact factor: 5.325

5.  Oral treatment with SEW2871, a sphingosine-1-phosphate type 1 receptor agonist, ameliorates experimental colitis in interleukin-10 gene deficient mice.

Authors:  J Dong; H Wang; G Wu; J Zhao; L Zhang; L Zuo; W Zhu; J Gong; Y Li; L Gu; J Li
Journal:  Clin Exp Immunol       Date:  2014-07       Impact factor: 4.330

6.  Bioengineering Bacterially Derived Immunomodulants: A Therapeutic Approach to Inflammatory Bowel Disease.

Authors:  Lina Herrera Estrada; Huixia Wu; Kevin Ling; Guikai Zhang; Ronen Sumagin; Charles A Parkos; Rheinallt M Jones; Julie A Champion; Andrew S Neish
Journal:  ACS Nano       Date:  2017-09-05       Impact factor: 15.881

7.  Technical considerations in children undergoing laparoscopic ileal-J-pouch anorectal anastomosis for ulcerative colitis.

Authors:  Girolamo Mattioli; Edoardo Guida; Alessio Pini-Prato; Stefano Avanzini; Valentina Rossi; Arrigo Barabino; Arnold G Coran; Vincenzo Jasonni
Journal:  Pediatr Surg Int       Date:  2011-11-30       Impact factor: 1.827

8.  Does Medical Acceleration Improve Outcomes in Ulcerative Colitis Patients Who Are in Clinical Remission but Have Endoscopic Inflammation?

Authors:  Ji Young Chang; Jae Hee Cheon; Yehyun Park; Soo Jung Park; Tae-Il Kim; Won-Ho Kim
Journal:  Dig Dis Sci       Date:  2018-07-09       Impact factor: 3.199

Review 9.  Cytoskeletal Organization and Cell Polarity in the Pathogenesis of Crohn's Disease.

Authors:  Chengcen Guo; Jun Shen
Journal:  Clin Rev Allergy Immunol       Date:  2021-04       Impact factor: 8.667

10.  Metabolic control of T cell immune response through glycans in inflammatory bowel disease.

Authors:  Ana M Dias; Alexandra Correia; Márcia S Pereira; Catarina R Almeida; Inês Alves; Vanda Pinto; Telmo A Catarino; Nuno Mendes; Magdalena Leander; M Teresa Oliva-Teles; Luís Maia; Cristina Delerue-Matos; Naoyuki Taniguchi; Margarida Lima; Isabel Pedroto; Ricardo Marcos-Pinto; Paula Lago; Celso A Reis; Manuel Vilanova; Salomé S Pinho
Journal:  Proc Natl Acad Sci U S A       Date:  2018-05-02       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.